A combined immune prognostic index in esophageal squamous cell carcinoma patients treated with anti-PD-1 therapy

Author:

Ji Shoujian12,Zhao Chuanhua2,Liu Rongrui2,Wang Yan3,Yang Qing4,Yang Hua5,Xu Jianming6ORCID

Affiliation:

1. Department of Gastroenterology, The 960th Hospital of the PLA, Jinan, China

2. Department of Gastrointestinal Oncology, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China

3. Innovent Biologics, Inc., Suzhou, China

4. Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China

5. Department of Outpatient, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Street, Haidian District, Beijing 100853, China

6. Department of Gastrointestinal Oncology, The Fifth Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Street, Haidian District, Beijing 100853, China

Abstract

Background: Only a fraction of patients with esophageal squamous cell carcinoma (ESCC) show tumor responses to anti-programmed cell death protein 1 (PD-1) therapy. The predictive value of single biomarkers for prognosis is limited, and a more comprehensive approach that incorporates multiple factors may improve the prognostic prediction. Here, we conducted a retrospective study to develop a combined immune prognostic index (CIPI) for predicting clinical outcomes of ESCC patients treated with anti-PD-1 therapy. Design and methods: We performed a pooled analysis of two multicenter clinical trials comparing immunotherapy versus chemotherapy as second-line treatment in ESCC patients. The discovery cohort comprised patients who received anti-PD-1 inhibitors ( N = 322) and the control cohort comprised patients who received chemotherapy ( N = 307). The validation cohort included patients with pan-cancers treated with PD-1/programmed cell death ligand-1 inhibitors, except for ESCC ( N = 110). Multivariable Cox proportional hazard regression was used to assess the prediction value of variables on survival. Results: In the discovery cohort, neutrophil-to-lymphocyte ratio, serum albumin, and liver metastasis were independently associated with overall survival (OS) and progression-free survival (PFS). We integrated the three variables into CIPI and found that CIPI could categorize patients into four subgroups (CIPI 0 to CIPI 3) with distinct OS, PFS, and tumor responses. The CIPI was also predictive of clinical outcomes in the validation cohort, but not in the control cohort. Furthermore, patients with CIPI 0, CIPI 1, and CIPI 2 were more likely to benefit from anti-PD-1 monotherapy than chemotherapy, while patients with CIPI 3 did not benefit from anti-PD-1 monotherapy over chemotherapy. Conclusions: The CIPI score was a robust biomarker for prognostic prediction in ESCC patients treated with anti-PD-1 therapy and was immunotherapy specific. The CIPI score may also be applicable for prognostic prediction in pan-cancers.

Funder

National Natural Science Foundation of China

Publisher

SAGE Publications

Subject

Oncology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3